TON Strategy Company TONX 深 沪
已收盘 02-06 16:00:00 美东时间
1.96
+0.160
+8.89%
华盛通- 最 高2.055
- 今 开1.84
- 成交量 62.12万股
- 最 低 1.83
- 昨 收 1.80
- 总市值 1.16亿
- 52周最高 29.77
- 市盈率 静 --
- 换手率 1.05%
- 52周最低 1.775
- 委 比 -24.87%
- 总股本 5909.05万
- 历史最高 29.77
- 量 比 1.03
- 振 幅 12.50%
- 历史最低 0.0407
- 每 手 1
- 风险率 4.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多TON Strategy launches leadership transition and governance overhaul
TON Strategy Company ( ($TONX) ) has issued an announcement. On January 26, 202...
01-29 05:57
TON Strategy CEO Veronika Kapustina Will Transition Out Of Role As Part Of Leadership Shuffle; Company Commences Search For New CEO
TON Strategy Company (Nasdaq: TONX), a digital asset treasury company dedicated to holding Toncoin ($TON), today announced leadership and governance actions intended to strengthen the Company's public-company foundation.
01-29 05:26
TON Strategy Company Announces Leadership Transition and Other Updates
<p><p align="justify">TON Strategy Company (NASDAQ: TONX) announced leadership changes, including the search for new independent directors and a CEO to strengthen governance and growth. Current CEO Veronika Kapustina will transition out of her role after a period to ensure continuity. The company, which holds Toncoin ($TON), continues its digital asset strategy and operates MARKET.live and LyveCom. Risks include regulatory challenges and market v...
01-28 21:05
TON Strategy Company Announces Senior Officer Appointments
TON Strategy Company appoints Mary L. Marbach as General Counsel and Corporate Secretary, and Bill J. Rivard as Chief Accounting Officer. Marbach brings over 20 years of legal experience, including roles at Savant Science Inc. and Vitacost.com, Inc. Rivard, with over 30 years in accounting, previously served as Interim CFO and has been involved in SEC reporting and internal controls. Both appointments aim to strengthen the company’s leadership an...
01-08 13:30
TON Strategy Q3 EPS $2.23 Beats $(1.90) Estimate, Sales $3.609M Beat $1.400M Estimate
TON Strategy (NASDAQ:TONX) reported quarterly earnings of $2.23 per share which beat the analyst consensus estimate of $(1.90) by 217.37 percent. This is a 158.38 percent increase over losses of $(3.82) per share from
2025-11-12 21:11
TON Strategy Company Receives Nasdaq Reprimand for Violations
TON Strategy Company ( ($TONX) ) has issued an update. On October 28, 2025, TON...
2025-10-30 00:49
12 Information Technology Stocks Moving In Wednesday's Pre-Market Session
Gainers Cambium Networks (NASDAQ:CMBM) stock increased by 299.7% to $2.47 duri...
2025-10-29 20:05
TON Strategy Company Holds Annual Stockholders Meeting
TON Strategy Company ( ($TONX) ) has provided an announcement. On October 24, 2...
2025-10-29 00:47
Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital
Tonix Pharmaceuticals has initiated the FOCUS study to evaluate intranasal potentiated oxytocin products (TNX-1900/TNX-2900) in patients with arginine-vasopressin deficiency (AVP-D), a rare disorder linked to oxytocin deficiency and mental health challenges. The randomized, double-blind, placebo-controlled crossover pilot trial aims to assess the effects of single and two-week doses of oxytocin on anxiety, depression, and socioemotional functioni...
2025-10-22 11:00
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence
Tonix Pharmaceuticals announced that Dr. Gregory Sullivan will present a poster on Tonmya™ (cyclobenzaprine HCl sublingual tablets) at the 2025 American College of Rheumatology Convergence in Chicago. The presentation will highlight Tonmya's effectiveness in reducing pain and its favorable tolerability in fibromyalgia patients. Tonmya is FDA-approved as a first-in-class, non-opioid treatment for fibromyalgia and is part of Tonix's pipeline target...
2025-10-21 11:00
